Graft Versus Host Disease Market to Surpass USD 4 Billion by 2036, Driven by Emerging Cell-Based Therapies and Rising HSCT Procedures

The Graft Versus Host Disease market across the 7MM is witnessing robust growth, fueled by rising hematopoietic stem cell transplant volumes, increasing disease burden, and the advancement of innovative therapies such as MaaT013 (XERVYTEG), RGI-2001, CYP-001, and other next-generation immunomodulatory treatments.Key companies operating in the Graft Versus Host Disease (GvHD) market include AbbVie, Johnson & Johnson, Sanofi, Incyte, Novartis, Syndax Pharmaceuticals, Bristol Myers Squibb, Shionogi, JCR Pharmaceuticals, Neovii, Mundipharma, and Platinum Life Excellence Biotech, among others.
DelveInsight's latest report, "Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast - 2036," provides a comprehensive analysis of the evolving Graft Versus Host Disease (GvHD) market landscape across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
According to DelveInsight's analysis, the Graft Versus Host Disease market in the 7MM was valued at approximately USD 2.1 billion in 2025 and is projected to expand at a CAGR of 6.4% during 2026-2036. The market growth is primarily driven by increasing numbers of hematopoietic stem cell transplantation (HSCT) procedures, a growing diagnosed patient population, improved disease awareness, and the introduction of targeted and cell-based therapies.

Access the Complete Graft Versus Host Disease Market Forecast Report: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Highlights from the Graft Versus Host Disease Market Report
• The GvHD market across the 7MM was valued at approximately USD 2.1 billion in 2025.
• The market is expected to grow at a CAGR of 6.4% through 2036.
• The United States represents the largest market, accounting for nearly 77% of the total 7MM market share.
• Approximately 52,000 GvHD cases were reported across the 7MM in 2025.
• Ruxolitinib (JAKAFI/JAKAVI) remains the leading revenue-generating therapy, followed by REZUROCK.
• Emerging therapies such as MaaT013 (XERVYTEG), RGI-2001, and CYP-001 are expected to reshape future treatment paradigms.
• Growing adoption of targeted immunotherapies and cell-based therapies continues to accelerate market expansion.

Rising Disease Burden Continues to Drive Graft Versus Host Disease Market Expansion
Graft Versus Host Disease is a serious immune-mediated complication that occurs following allogeneic hematopoietic stem cell transplantation when donor immune cells attack healthy recipient tissues. The disease commonly affects the skin, liver, gastrointestinal tract, lungs, oral mucosa, and eyes, leading to substantial morbidity and long-term complications.
As per DelveInsight estimates, approximately 52,000 total GvHD cases were reported across the 7MM in 2025. The patient pool is expected to increase throughout the forecast period due to rising transplant procedures and improved post-transplant survival rates.
In the United States alone, there were approximately:
• 4,300 acute GvHD cases in 2025
• 18,500 five-year prevalent chronic GvHD cases

Request a Sample Copy of the Graft Versus Host Disease Market Report: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Graft Versus Host Disease Current Treatment Landscape Continues to Evolve
The treatment paradigm for GvHD has advanced considerably in recent years, moving beyond conventional corticosteroid-based approaches toward targeted immune modulation.
Leading therapies currently shaping the market include:

JAKAFI/JAKAVI (Ruxolitinib)
Developed by Incyte and Novartis, ruxolitinib remains one of the most widely adopted therapies for steroid-refractory acute and chronic GvHD due to its ability to inhibit JAK1/JAK2 signaling pathways and suppress cytokine-driven inflammation.

IMBRUVICA (Ibrutinib)
Developed by AbbVie and Janssen, IMBRUVICA serves as an important treatment option for chronic GvHD patients who have failed prior systemic therapies.

RYONCIL/TEMCELL HS (Remestemcel-L)
Mesoblast and JCR Pharmaceuticals continue to advance mesenchymal stromal cell therapy as an innovative treatment option for steroid-refractory acute GvHD.
In addition, recently approved therapies such as REZUROCK (Belumosudil) and NIKTIMVO (Axatilimab-csfr) are further transforming the treatment landscape by targeting key pathogenic pathways involved in chronic GvHD.

Explore Emerging Therapies and Future Market Opportunities: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Robust Pipeline Creates Long-Term Growth Opportunities
The GvHD pipeline remains highly active, with multiple late-stage candidates expected to significantly influence future market dynamics.

MaaT013 (XERVYTEG) - MaaT Pharma
MaaT013 is a first-in-class microbiota-based therapy designed to restore gut microbial balance and promote immune tolerance in gastrointestinal acute GvHD.
Recent milestones include:
• EMA Marketing Authorization Application submission in June 2025
• EUR 37.5 million financing secured from the European Investment Bank in July 2025
• Exclusive commercialization agreement signed with Clinigen in July 2025

RGI-2001 - REGiMMUNE
RGI-2001 is an innovative regulatory T-cell (Treg)-inducing therapy aimed at preventing acute GvHD while preserving beneficial graft-versus-leukemia effects.
Recent developments include:
• Positive Phase IIb results reported in February 2024
• Ongoing preparations for Phase III development
• Expanded commercialization efforts across major Asian markets

CYP-001 - Cynata Therapeutics
CYP-001 is a stem cell-based immunomodulatory therapy currently being evaluated in Phase II studies for high-risk acute GvHD.
These novel therapies represent a shift toward immune tolerance induction, tissue repair, and precision-based disease management.

Graft Versus Host Disease Competitive Landscape
Several pharmaceutical and biotechnology companies are actively competing within the GvHD market, including:
• AbbVie
• Johnson & Johnson
• Sanofi
• Incyte
• Novartis
• Syndax Pharmaceuticals
• Bristol Myers Squibb
• Shionogi
• JCR Pharmaceuticals
• Neovii
• Mundipharma
• Platinum Life Excellence Biotech
• And others
Strategic partnerships, regulatory approvals, and clinical advancements continue to intensify competition within the market.

Download Detailed Epidemiology and Market Forecast Analysis: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Graft Versus Host Disease Recent Industry Developments
• May 2026: Australia approved a new first-in-class therapy for chronic GvHD patients who failed corticosteroids or other systemic therapies, providing an important advancement in post-transplant care.
• July 2025: MaaT Pharma entered into an exclusive commercialization and supply agreement with Clinigen for MaaT013.
• June 2025: MaaT Pharma submitted a Marketing Authorization Application to the EMA for MaaT013.
• April 2024: REGiMMUNE presented Phase IIb findings for RGI-2001 at the AACR Annual Meeting.
• February 2024: REGiMMUNE announced positive Phase IIb efficacy data supporting further development of RGI-2001.

Graft Versus Host Disease Market Outlook
The GvHD market is entering a transformational phase characterized by the emergence of targeted biologics, microbiome therapeutics, stem cell therapies, and immune tolerance-inducing approaches. As healthcare providers increasingly move beyond broad immunosuppression strategies, innovative therapies are expected to improve patient outcomes while creating substantial commercial opportunities.
Growing transplant activity, increasing disease awareness, expanding reimbursement support, and continued pipeline innovation are anticipated to drive sustained market growth across the 7MM through 2036.

Related Reports
• Graft versus host disease Pipeline Insight, 2026
DelveInsight's, "Graft versus host disease (GVHD) Pipeline Insight, 2026," report provides comprehensive insights about 45+ GvHD companies and 50+ pipeline drugs in Graft versus host disease (GVHD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
•Graft Versus Host Disease (GvHD) - Epidemiology Forecast to 2034
DelveInsight's 'Graft Versus Host Disease (GvHD) - Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted GvHD epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Table Of Content
1. Key Insights
2. Report Introduction
3. GvHD Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Disease Overview and Background
7. Epidemiology and Market Forecast Methodology
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Drugs
11. Emerging Drugs
12. GvHD - 7MM Market Analysis
13. Key Opinion Leaders' Views
14. Unmet Needs
15. SWOT Analysis
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: +1-919-321-6187
Website: www.delveinsight.com

About DelveInsight
DelveInsight is a leading life sciences market research and business consulting company recognized for its syndicated market research reports and customized healthcare intelligence solutions. The company provides actionable insights across pharmaceuticals, biotechnology, medical devices, diagnostics, and digital health sectors to support strategic decision-making and business growth.

This release was published on openPR.